Trial exclusion patterns Phase 2 and Phase 3 retatrutide trials commonly excluded participants with a history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), severe gastroparesis, recent major cardiovascular events, severe kidney impairment, type 1 diabetes (in the obesity studies), and pregnancy or breastfeeding
Stinson, where you are treating a child and you see a mother whom you can tell is having health issues, even without an exam
Jung S, Whiteaker JR, Zhao L, Yoo HW, Paulovich AG, Hahn SH
US regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity